Ticker brief
CAPR CAPRICOR THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$5.93
1 day
-3.3%
14 days
-24.3%
mkt cap
·
signals 14d
12
authors 14d
7
crowd 14d
+1.7σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-03 → 2026-10-16 · now +0.00 (−1 bearish … +1 bullish)
Who spoke7
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PK_Fund | C | -0.52 | 3 | +0.48 |
| @BPharmCatalyst | C | · | 3 | +0.00 |
| @YYDSxjm | B | -0.25 | 2 | +0.85 |
| @BiopharmIQ | B | · | 1 | -0.50 |
| @QuasarMarkets | C | +3.67 | 1 | -0.10 |
| @OzmosiHealth | C | · | 1 | +0.00 |
| @OptionsHawk | B | -1.11 | 1 | +0.30 |
Recent signals12of 12 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BPharmCatalyst | +0.00 | Publishes a biotech watchlist for catalysts expected in mid-winter 2026. | -11.6% | tweet ↗ |
| 2026-10-14 | @BPharmCatalyst | +0.00 | Flags three biotech companies with potentially market-moving FDA decisions due in November. | -10.0% | tweet ↗ |
| 2026-10-13 | @PK_Fund | +0.20 | Reports that Capricor posted the PPMD webinar and slides online. | -13.8% | tweet ↗ |
| 2026-10-11 | @PK_Fund | +0.55 | Argues deramiocel merits full regulatory approval based on sustained efficacy data. | -24.3% | tweet ↗ |
| 2026-10-11 | @YYDSxjm | +0.90 | Discloses a 10,000-plus-share holding and strongly expects FDA approval this month. | -24.3% | tweet ↗ |
| 2026-10-09 | @BPharmCatalyst | +0.00 | Six-month watchlist of upcoming PDUFA catalyst decisions; ticker list capped at six. | -24.3% | tweet ↗ |
| 2026-10-07 | @OptionsHawk | +0.30 | States CAPR puts were sold and touts 99% classification accuracy after software tweaks. | -26.8% | tweet ↗ |
| 2026-10-06 | @YYDSxjm | +0.80 | Defends CAPR's regulatory strategy and argues hidden sensitivity analyses support the HOPE-3 result. | -23.5% | tweet ↗ |
| 2026-10-06 | @PK_Fund | +0.70 | Expresses strong hope for imminent FDA approval while citing prior internal timing. | -23.5% | tweet ↗ |
| 2026-10-06 | @OzmosiHealth | +0.00 | Capricor presented Phase 3 deramiocel Duchenne results on 2026-10-05. | -23.5% | tweet ↗ |
| 2026-10-05 | @QuasarMarkets | -0.10 | Lists dated 2026 regulatory decisions for CAPR and IRD drug candidates. | -23.8% | tweet ↗ |
| 2026-10-03 | @BiopharmIQ | -0.50 | Summarizes modeled November FDA odds and move profiles for three biotech catalysts. | -33.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.